Adocia SA · EURONEXT:ADOC

Adocia SA — Investor Presentation (January 2022)

39 slides from Adocia SA's investor presentation, January 2022

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    Corporate Presentation January 2022

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer This corporate presentation (the “Presentation”) has The Presentation does not purport to contain well as the trends in the sector in which the Group been prepared by ADOCIA S.A. (the “Company” and, comprehensive or complete information about the operates, may differ materially from those

  3. Slide 3: Highly experienced management team

    Slide 3: Highly experienced management team

    Highly experienced management team Gérard Soula Olivier Soula Valérie PhD, MBA PhD, MBA Danaguézian Deputy General Manager, President & CEO Director of R&D Chief Financial Officer Co-founder Co-founder Jérémy Benattar Michael PharmD, Eng Nguyen Director of Marketing & Head of BD,US Strategy • Co-fou

  4. Slide 4: Executive Summary

    Slide 4: Executive Summary

    Executive Summary Our mission: to develop innovative formulations of approved 1 hormones for the treatment of diabetes and obesity 2 Our business model: product licensing after proof-of-concept Our pipeline is based on our 3 patented technology platforms: 3 • 1 product approved to enter in Phase 3 i

  5. Slide 5: Adocia's vision: addressing metabolic diseases from hormonal to cell therapies

    Slide 5: Adocia's vision: addressing metabolic diseases from hormonal to cell therapies

    Adocia’s vision: addressing metabolic diseases from hormonal to cell therapies Improving islets of Langerhans transplant with hydrogel matrix for diabetes Oral Formulations of hormones for diabetes and obesity Hormones combinations for diabetes and obesity Improving insulin-therapy Adocia is taking

  6. Slide 6: Diabetes and Obesity: worldwide chronic pandemics

    Slide 6: Diabetes and Obesity: worldwide chronic pandemics

    Diabetes and Obesity: worldwide chronic pandemics 463 million people live with diabetes1 Diabetes is closely linked to obesity 1 in 11 • In the US, 65% of adults with type 13 diabetes and 85% of type 24 are overweight or obese • Several hormones are involved in both diabetes and obesity treatment 1.

  7. Slide 7: A well-advanced and diversified pipeline with products ready to partner

    Slide 7: A well-advanced and diversified pipeline with products ready to partner

    A well-advanced and diversified pipeline with products ready to partner Preclinic Phase 1 Phase 2 Phase 3 Upcoming milestones BC Lispro Phase 3 in China expected in 2022 Ultra-Rapid Insulin U100 / U200 Phase 3 in USA and Europe expected in 2022* Insulins Combination BC Combo U200 Phase 1 expected in

  8. Slide 8: BioChaperone platform potentializes performance of insulins and other hormones

    Slide 8: BioChaperone platform potentializes performance of insulins and other hormones

    BioChaperone® platform (BC) potentializes performance of insulins and other hormones BioChaperone® Proteins and peptides (insulin, amylin, GLP-1 RA, glucagon…) • Pharmaceutical excipient • 50 patents filed [BioChaperone® Protein] Complex  Improved solubility Accelerated absorption Improved stabil

  9. Slide 9: Diabetes

    Slide 9: Diabetes

    Diabetes Corporate Presentation 9

  10. Slide 10: BioChaperone Lispro

    Slide 10: BioChaperone Lispro

    BioChaperone® Lispro The next best-in-class Rapid Acting Insulin for a tighter glycemic control Corporate Presentation 10

  11. Slide 11: BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class

    Slide 11: BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class

    BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class Post-meal glycaemia in T1D • Better efficacy profile for less hyperglycemia and less hypoglycemia (“Faster-in” / “Faster- out”) vs. comparators • Good tolerance for optimized daily use AUC0-2h: -61%* • Range of strengths (U100

  12. Slide 12: BC Lispro, a competitor in the Ultra-Rapid Insulins class

    Slide 12: BC Lispro, a competitor in the Ultra-Rapid Insulins class

    BC Lispro, a competitor in the Ultra-Rapid Insulins class Only 3 ultra-rapid insulins will compete in the $9bn1 prandial insulin market, addressing the needs of 34 millions mealtime insulins users (T1D + T2D): BC Lispro • Licensed to Tonghua Dongbao (THDB) for development & commercialization for Chi

  13. Slide 13: BC Combo: basal-bolus insulin combination

    Slide 13: BC Combo: basal-bolus insulin combination

    BC Combo: basal-bolus insulin combination Insulins glargine & lispro Corporate Presentation 13

  14. Slide 14: BC Combo, a unique combination of glargine and lispro

    Slide 14: BC Combo, a unique combination of glargine and lispro

    BC Combo, a unique combination of glargine and lispro, the gold standards of basal and prandial insulins BioChaperone® Combo 1 product Once or twice a day U200 fixed ratio (150 U/mL glargine - 50 U/mL lispro) Less hyperglycemia  Simple  Affordable Less hypoglycemia  Limited number of injections 

  15. Slide 15: BC Combo is licensed to Tonghua Dongbao in China

    Slide 15: BC Combo is licensed to Tonghua Dongbao in China

    BC Combo is licensed to Tonghua Dongbao in China Premix market Tonghua Dongbao deal $2,7bn1 Western Markets: T2D patients • $40m upfront $2,3bn1 • $50m upcoming development Emerging Markets: milestones T1D & T2D ~65% • Double-digit royalties on sales patients Market share in India and China (volume)

  16. Slide 16: Multi-hormonal combinations

    Slide 16: Multi-hormonal combinations

    Multi-hormonal combinations Insulin in combination with other hormones Corporate Presentation 16

  17. Slide 17: Adocia has in hand the next generation of insulin-based treatment

    Slide 17: Adocia has in hand the next generation of insulin-based treatment

    Adocia has in hand the next generation of insulin-based treatment Multi-hormonal combinations Medical M1Pram, BC LisPram/ benefits BC AsPram Ultra-Rapid Insulins BC Lispro, Fiasp®, Lyumjev® Rapid Acting Insulins Humalog®, Novolog® & biosimilars Human Insulins Animal Insulins Humulin®, Novolin® Hypur

  18. Slide 18: M1Pram, BC LisPram / BC AsPram

    Slide 18: M1Pram, BC LisPram / BC AsPram

    M1Pram BC LisPram / BC AsPram Insulin-Amylin 2-in-1 products: a therapeutic breakthrough Corporate Presentation 18

  19. Slide 19: Glycemic control requires the synchronized action of insulin and amylin

    Slide 19: Glycemic control requires the synchronized action of insulin and amylin

    Glycemic control requires the synchronized action of insulin and amylin Meal Without diabetes Pancreas Insulin Level of secretion (relative scale) Amylin Insulin Glucagon Produced 0 1 2 3 4 5 6 Produced Glucagon by α-cells Time (hours) by β-cells Meal With diabetes Level of secretion Glucagon is dys

  20. Slide 20: Symlin (pramlintide) was approved by FDA in 2005 as an adjunct to insulin

    Slide 20: Symlin (pramlintide) was approved by FDA in 2005 as an adjunct to insulin

    Symlin® (pramlintide, an amylin analog) was approved by FDA in 2005 as an adjunct to insulin treatment for T1D and T2D The amylin effects in physiology The evidences demonstrated by pramlintide Activates amylin receptors in different brain areas  Satiety  Improvement of HbA1c  Protects cognitive

  21. Slide 21: Adocia is developing insulin-amylin combinations for pen and pump

    Slide 21: Adocia is developing insulin-amylin combinations for pen and pump

    Adocia is developing insulin-amylin combinations for pen and pump Optimal product profile for MDI in pen Optimal product profile for pump Regular insulin analog + Pram Rapid insulin analog + Pram M1Pram BC LisPram BC AsPram Q1 2022: Phase 2 T1D results Q2 2022: Phase 1 T1D results MDI: Multiple Dail

  22. Slide 22: Promising Phase 1b results of M1Pram in pen vs Novolog

    Slide 22: Promising Phase 1b results of M1Pram in pen vs Novolog

    Promising Phase 1b results of M1Pram in pen vs Novolog Phase 1b – CT038: n=40 T1D 3-week outpatient trial - M1Pram vs. Novolog (Part B n=16; High dose of insulin) Average glycemia Weight Time In Range 164 0,5 16,2 162 0,4 16 0 15,8 160 -7 mg/dL -2 kg 15,6 +58 min -0,5 Hours 158 mg/dL p=0,01 p=0,0065

  23. Slide 23: M1Pram offers better glycemic control and weight loss

    Slide 23: M1Pram offers better glycemic control and weight loss

    M1Pram offers better glycemic control and weight loss M1Pram leverages pramlintide’s clinical benefits “This combination has the potential to Targeted phase 2 results: finally deliver on the promise of pramlintide for a large number of patients.”  HbA1c decrease: [-0,3% ; -0,5%] Prof. Robert Ratner

  24. Slide 24: BC LisPram: the optimal combination for pumps

    Slide 24: BC LisPram: the optimal combination for pumps

    BC LisPram: the optimal combination for pumps Clinical Proof-of-Concept established at Mc Gill University, Canada, by Dr. Ahmad Haidar, comparing Lispro in one pump vs. Lispro and Pramlintide administered simultaneously in two separate pumps, over one month1 n=29 T1D Results • 10% improvement of Tim

  25. Slide 25: Cell Therapy

    Slide 25: Cell Therapy

    Cell Therapy Innovative Scaffold for Pancreatic Cell Therapy Corporate Presentation 25

  26. Slide 26: Adocia developed an innovative hydrogel scaffold to protect and host islets

    Slide 26: Adocia developed an innovative hydrogel scaffold to protect and host islets

    Adocia developed an innovative hydrogel scaffold to protect and host islets of Langerhans transplants Hydrogel scaffold Transplant Organoid Islets sourcing (Allogenic/stem-cell) External source Adocia’s goal is to propose a life saving therapy to insulino-resistant patients Corporate Presentation 26

  27. Slide 27: Development achievements of the hydrogel scaffold

    Slide 27: Development achievements of the hydrogel scaffold

    Development achievements Innovative Hydrogel  Well tolerated Insulin secretion Encapsulated Islets in response to glucose Naked Islets  Long term stability and fully retrievable  Patents application filed 3G 15G 3G 6 Islets encapsulation Normalized insulin secretion 5  Simple and cell-friendly p

  28. Slide 28: Obesity

    Slide 28: Obesity

    Obesity Personalized multi-hormonal obesity treatment: a new paradigm “At Adocia, we believe that long lasting victory against obesity will come from the patients – so let’s give them the tools they need” Corporate Presentation 29

  29. Slide 29: Combinations of diabetes hormones appear to be a revolutionary way to treat obesity

    Slide 29: Combinations of diabetes hormones appear to be a revolutionary way to treat obesity

    Combinations of “diabetes” hormones appears to be a revolutionary way to treat obesity Product Class Mean Mean Weight Loss Weight Loss expected Targeted (standalone) (combo) AMYLIN PramExe Amylin analog -7,9%1 -15% Pramlintide Exenatide GLP1-RA - 8%2 Diabetes GLP-1 Obesity BC GluExe Glucagon -7 to -

  30. Slide 30: First Proof-of-Concept in obese mice with BC Glucagon Exenatide

    Slide 30: First Proof-of-Concept in obese mice with BC Glucagon Exenatide

    A first Proof-of-Concept has been established in obese mice with Biochaperone® Glucagon Exenatide (BC GluExe) 120 110 100 Saline (vehicle) BC Exenatide* Exenatide “standalone” showed a significant 90 -10% Exenatide -10% weight loss compared to vehicle BW (%) 80 70 -25% BC Glucagon Exenatide*** showe

  31. Slide 31: Adocia is developing patient-centric treatments

    Slide 31: Adocia is developing patient-centric treatments

    Adocia is developing patient-centric treatments CURRENT PARADIGM ADOCIA’S PARADIGM Long acting GLP-1 RA are being developed to limit the The patient wears a patch-pump number of injections to deliver combinations of short acting hormones However, despite demonstrated efficacy, GLP-1 RA class goes al

  32. Slide 32: Patient's reasons to adopt short-acting hormones in pump

    Slide 32: Patient's reasons to adopt short-acting hormones in pump

    Patient’s reasons to adopt short-acting hormones in pump n days infusion n days infusion 1 day off Concentration 4x Patient can: • Intensify the treatment by increasing Concentration 2x the dosage to obtain maximum results Concentration 1x • Stop temporarily by switching it off, to suspend immediate

  33. Slide 33: Oral delivery

    Slide 33: Oral delivery

    Oral delivery Corporate Presentation 34

  34. Slide 34: Adocia's oral delivery technology of hormones for diabetes and obesity

    Slide 34: Adocia's oral delivery technology of hormones for diabetes and obesity

    Adocia’s oral delivery technology of hormones for diabetes and obesity The context Adocias’ proposal • Peptides and proteins widely used as drugs but only • Adocia has developed a formulation enhancing the available in injectable forms efficiency of peptides absorption by the  Burden for patients g

  35. Slide 35: Financial & news flow

    Slide 35: Financial & news flow

    Financial & news flow Corporate Presentation 36

  36. Slide 36: News flow

    Slide 36: News flow

    News flow BC Lispro M1Pram PramExe – BC GluExe • In China: Phase 3 start • Phase 2 study in T1D in MDI • In-Human Proof-of-concept expected in 2022 (Multiple Daily Injection) in 2022 ongoing • In USA/EU: Phase 3 launch scheduled in 2022 • Results expected Q1 2022 Cell Therapy • FIH study 2022 BC Com

  37. Slide 37: Key financials & shareholder information

    Slide 37: Key financials & shareholder information

    Key financials & shareholder information Key financials features1 Shareholder ownership Market information Already received • Listed on Euronext Paris (ADOC) • €85m raised since inception Soula Family • 7.2m shares outstanding • $120m received from partnership 22,5% • ADR program in the US (ADOCY) E

  38. Slide 38: Summary

    Slide 38: Summary

    Summary • A well-advanced and diversified pipeline with products ready-to-license: • 5 products with clinical proof-of-concept based on its proprietary BioChaperone® platform o BC Lispro is planned to enter in Phase 3 in China in 2022 and Adocia is seeking partners for Europe, US, Japan o BC Combo c

  39. Slide 39: Thank you for your kind interest

    Slide 39: Thank you for your kind interest

    Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com

Source: Internet Archive copy of adocia.com

More decks from Adocia SA

All 49 Adocia SA decks